Replimune looks to rope in $225M on the back of melanoma da­ta

The Mass­a­chu­setts-based, on­colyt­ic virus biotech Replimune is feel­ing bull­ish now that it has lift­ed the cov­er on da­ta for its lead prod­uct.

Replimune said Thurs­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER